Appendix 2A — Fully Paid Ordinary Shares
Imagion Biosystems Limited announces Appendix 2A — Fully Paid Ordinary Shares. Read the announcement.
Imagion Biosystems Limited announces Appendix 2A — Fully Paid Ordinary Shares. Read the announcement.
Imagion Biosystems Limited announces the proposed issue of 1,500,000 options expiring 28 April, 2023. Read the announcement.
Imagion Biosystems Limited announces the proposed issue of 1,000,000 ordinary fully paid securities. Read the announcement.
Imagion Biosystems Limited (ASX: IBX) (the Company) advises in accordance with Listing Rule 3.10A, that 2,500,000 Fully Paid Ordinary Shares will be released from voluntary
Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in Australia
Imagion Biosystems Limited has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
$5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP. Strongly
The application for quotation (Appendix 2A) for listed options (IBCOA) was released to the market. Read Appendix 2A.
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement regarding a
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
We have temporarily suspended our nanoparticle operations. Please revisit us in the future. We apologize for the inconvenience. Any questions, please email: info@imagionbio.com Dismiss